NS Pharma and Boston Children’s Hospital Partner to Advance Rare Disease Therapies

NS Pharma Inc., a U.S. subsidiary of Nippon Shinyaku Co. Ltd., has announced a strategic alliance with Boston Children’s Hospital to accelerate the development of innovative treatments for rare diseases. The collaboration, facilitated by NS Pharma’s Innovation Research Partnering team in Cambridge, MA, will align both organizations' research priorities.

Under the agreement, Boston Children’s will propose research projects, which Nippon Shinyaku will review for potential joint development—ranging from early-stage disease mechanism studies to novel therapeutic target validation.

This partnership reflects Nippon Shinyaku’s commitment to addressing rare and hard-to-treat diseases. The company is already marketing Viltepso, a nucleic acid drug for Duchenne muscular dystrophy, in Japan and the U.S.

08-07-2025